Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations.

Biomed Industries Unveils novel Quadruple Receptor Agonist for weight loss with Minimal Adverse Effects at the International Obesity conference in Las Vegas Dr. Lloyd L. Tran Biomed Industries, Inc.

Data from the US FDA's Adverse Event Reporting System on tirzepatide showed adverse events generally consistent with those ...

A new study explores the reasons why tirzepatide, the once-weekly injection used to treat obesity and type 2 diabetes, is ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

Representational Photo The exploration of novel peptides for their potential impact on metabolic pathways has been a ...

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage ...

Tirzepatide, a novel GLP-1/GIP dual receptor agonist, shows significant advantages in glycemic management and weight control. By summarizing the results of the SURMOUNT and SURPASS clinical trials, we ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.